By Daniella Parra Lunaphore said it completed CHF40 million in Series D1 funding led by Ernst-Göhner Stiftung Beteiligungen (EGSB). The Swiss life sciences company said it plans to use the funding to strengthen its portfolio offering in spatial biology and support...

  By Healthcare Edge Editorial Staff Biopharma company Ocean Biomedical (Nasdaq: OCEA) began trading publicly today after merging with a SPAC called Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA). Ocean Biomedical is focused on the commercialization of assets from research universities...

Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to reach through blood-brain barrier Targets 2 rare cancers: recurrent glioblastoma...

By IPO Edge Editorial Staff Biopharmaceutical company AEON Biopharma, Inc. has raised an additional $20 million in funding from existing investors to support its going-public transaction with Priveterra Acquisition Corp. (Nasdaq: PMGM). The additional capital represents nearly half of the...

By Exec Edge Editorial Staff Immunotherapy-focused SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...